Table 2.
Multivariable* Cox regression analyses
| Hazard of Developing Non- exudative AMD Model |
Hazard of Developing Exudative AMD Model |
Progression From Non-exudative to Exudative AMD Model |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hazard Ratio |
95% Confidence Limits |
p-Value | Hazard Ratio |
95% Confidence Limits |
p-Value | Hazard Ratio |
95% Confidence Limits |
p-Value | |||||
| Statin Use | 0–6 months | REF | REF | REF | |||||||||
| 7–12 months | 0.93 | 0.81 | 1.07 | 0.324 | 0.99 | 0.69 | 1.41 | 0.952 | 1.04 | 0.62 | 1.75 | 0.870 | |
| 13–18 months | 0.99 | 0.86 | 1.14 | 0.886 | 1.57 | 1.16 | 2.13 | 0.003 | 1.27 | 0.78 | 2.06 | 0.337 | |
| 19–24 months | 0.97 | 0.87 | 1.07 | 0.515 | 1.48 | 1.17 | 1.88 | 0.001 | 1.63 | 1.16 | 2.29 | 0.005 | |
| LDL Level† | Optimal (<100) | REF | REF | REF | |||||||||
| Near Optimal (100–129) | 1.03 | 0.95 | 1.11 | 0.544 | 1.19 | 0.97 | 1.45 | 0.090 | 1.29 | 0.97 | 1.72 | 0.078 | |
| Borderline High (130–159) | 0.97 | 0.88 | 1.07 | 0.578 | 1.27 | 1.00 | 1.62 | 0.051 | 1.50 | 1.07 | 2.12 | 0.020 | |
| High (160–189) | 1.08 | 0.94 | 1.25 | 0.282 | 1.33 | 0.93 | 1.91 | 0.118 | 1.39 | 0.82 | 2.36 | 0.228 | |
| Very High (≥190) | 1.09 | 0.84 | 1.41 | 0.516 | 1.85 | 1.07 | 3.21 | 0.028 | 1.41 | 0.61 | 3.25 | 0.423 | |
| HDL | Low (<40) | REF | REF | REF | |||||||||
| Average (40–59) | 1.06 | 0.97 | 1.16 | 0.199 | 1.06 | 0.86 | 1.32 | 0.566 | 1.08 | 0.79 | 1.48 | 0.616 | |
| Optimal (≥60) | 1.13 | 1.03 | 1.25 | 0.014 | 1.06 | 0.83 | 1.35 | 0.663 | 1.02 | 0.72 | 1.45 | 0.896 | |
| Triglycerides | Normal (<150) | REF | REF | REF | |||||||||
| Borderline High (150–199) | 0.93 | 0.85 | 1.02 | 0.136 | 0.83 | 0.66 | 1.05 | 0.115 | 0.77 | 0.54 | 1.08 | 0.133 | |
| High (200–499) | 0.96 | 0.87 | 1.06 | 0.412 | 0.98 | 0.77 | 1.23 | 0.843 | 1.03 | 0.73 | 1.43 | 0.884 | |
| Very High (≥500) | 0.84 | 0.32 | 2.26 | 0.736 | 1.16 | 0.16 | 8.32 | 0.883 | 2.33 | 0.31 | 17.21 | 0.408 | |
*
Variables controlled for in multivariable analyses: age, sex, race, region of the country, education level, net worth, coagulopathies, skin cancer, iron deficiency anemia, blood loss anemia, renal disease, diabetes, hypertension, cerebrovascular accidents, myocardial infarct, congestive heart failure, peripheral vascular disease, obesity, hypotension, use of other lipid lowering medications, cataract, pseudophakia or aphakia, open angle glaucoma, diabetic eye disease
†
Enrollees hazard ratios were evaluated by assigning the most recent serum lipid level to that day, then calculating the enrollee’s hazard for developing non-exudative AMD, exudative AMD or progressing to exudative AMD on that day.